You are here:Home / Research / Diana Boraschi

Diana Boraschi

Research Focus : Innate Immunity and Inflammation

The Boraschi lab studies the mechanisms of innate defence responses, focussing in particular on the role of macrophages and inflammatory cytokines in the effector phase of defence reactions against infections and tumours. The main interests are the receptors of the IL-1R/TLR family and their cytokine ligands (IL-1 and IL-18). A fragment of IL-1 endowed with immunostimulatory activity is now defined as the “Boraschi loop”. The lab is currently studying the role of inflammation in the pathogenesis of diseases (from autoimmune syndromes to degenerative diseases such as ALS), with emphasis on abnormalities in the activation of macrophages. Within the study of the initiating mechanisms causing chronic inflammatory and autoimmune diseases, the lab has addressed the possible impact of engineered nanoparticles, and of their interaction with microbial derived factors, in initiating or modulating pathology-related inflammation. Diana Boraschi has initiated the “Immunosafety Focus Group” within the NanoSafety Cluster, a EU-sponsored initiative aiming at defining and standardisingthe immunosafety assessment as central part of nanosafety regulations (http://www.nanosafetycluster.eu/working-groups/2-hazard-wg/immunosafety.html).

For the ongoing EU-funded research projects of the Boraschi lab, please visit the following web pages:

http://www.humunity.eu/

http://www.biocog.eu/

http://www.nanotoes.eu/

http://nanoreg.eu/

Curriculum

Diana Boraschi is an immunologist that built her experience both in academic institutions (Italian National Council for Nuclear Energy, Rome, Italy; National Cancer Institute in Bethesda, MD; Mario Negri Institute in Milano; University of Michigan Medical School, Ann Arbor, MI; National Research Council in Pisa and Napoli) and industrial settings (the vaccine company Sclavo in Siena; the pharmaceutical company Dompé in L’Aquila). She has served as Director of Fellowships at the Human Frontier Science Program Organization in Strasbourg, France. As external expert evaluator, she has served in the research programmes of the EU Commission (FP5, FP6, FP7, H2020, EDCTP), the Singapore National Medical Council, the US National Science Foundation, and governmental initiatives in Belgium, Czech Republic, Egypt, Italy, Poland, South Africa, Sweden, Switzerland, and Romania. She also serves as peer reviewer for 101 scientific journals and is on the editorial board of eight of them. She is author of 160 peer-reviewed research articles in immunology, editor/author of 20 books, and inventor in eight patents, in addition to numerous monographic and divulging publications. She has an h-index of 49, an i10-index of 129, a g-index of 74, and a total of 6924 citations. Since many years she is involved in international higher education training activities, with particular emphasis on capacity building actions in Africa in the field of poverty-related diseases and health care systems and delivery.

Key Publications since 2010

  • Boraschi D, Meltzer MS (1979) “Defective tumoricidal capacity of macrophages from A/J mice. II. Comparison of the macrophage cytotoxic defect of A/J mice with that of lipid A-unresponsive C3H/HeJ mice” J. Immunol. 122: 1592-1597. PMID: 376721
    THE PAPER THAT POSED THE BASIS FOR THE LATER IDENTIFICATION OF TLR IN MAMMALS AND OF THE MECHANISMS OF INNATE MEMORY OF MACROPHAGES
     
  • Luini W, Boraschi D, Alberti S, Aleotti A, Tagliabue A (1981) “Morphological characterization of a cell population responsible for mouse natural killer activity” Immunology 43: 663-668. PMID: 7275171  
    THE FIRST IDENTIFICATION OF LGL AS NK CELLS IN THE MOUSE
     
  • Bottazzi B, Polentarutti N, Acero R, Balsari A, Boraschi D, Ghezzi P, Salmona M, Mantovani A (1983) “Tumor-derived chemoattractants: a mechanism of regulation of the macrophage content of neoplasms” Science 220: 210-212. PMID: 6828888
    THE FIRST DESCRIPTION OF THE MECHANISM OF RECRUITMENT OF TUMOR-INFILTRATING MACROPHAGES AND THEIR ROLE IN TUMOR GROWTH
     
  • Tagliabue A, Nencioni L, Villa L, Keren DF, Lowell GH, Boraschi D (1983) “Antibody-dependent cell-mediated antibacterial activity of intestinal lymphocytes with secretory IgA” Nature 306: 184-186. PMID: 6646200
    DESCRIPTION OF A NOVEL MECHANISM OF ANTIBACTERIAL DEFENCE BY INTESTINAL INTRAEPITHELIAL LYMPHOCYTES ARMED WITH IGA
     
  • Boraschi D, Censini S, Tagliabue A (1984) “Interferon-g reduces macrophage suppressive activity by inhibiting prostaglandin E2 release and inducing interleukin 1 production” J. Immunol. 133: 764-768. PMID: 6437846
    THE STUDY THAT FIRST DESCRIBED THE MECHANISMS UNDERLYING THE DIFFERENT TYPES OF MACROPHAGE ACTIVATION, WHICH WERE LATER TERMED M1 AND M2 POLARISATION   

  • Antoni G, Presentini R, Perin F, Tagliabue A, Ghiara P, Censini S, Volpini G, Villa L, Boraschi D (1986) “A short synthetic peptide fragment of human interleukin 1 with immunomodulatory but not inflammatory activity” J. Immunol. 137: 3201-3204. PMID: 3490514
    THE PAPER THAT OPENED A LARGE LINE OF INVESTIGATION THAT EVENTUALLY CLARIFIED THE STRUCTURE-FUNCTION RELATIONSHIP IN THE INTERLEUKIN-1B MOLECULE
     
  • Giavazzi R, Garofalo A, Bani MR, Abbate M, Ghezzi P, Boraschi D, Mantovani A, Dejana E (1990) “Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice” Cancer Res. 50: 4771-4775. PMID: 2196116
    THE FIRST EVIDENCE OF THE PRO-METASTATIC CAPACITY OF IL-1
     
  • Lang D., Knop J, Wesche H, Raffetseder U, Kurrle R, Boraschi D, Martin MU (1998) “The type II interleukin-1 receptor interacts with the interleukin-1 receptor accessory protein: a novel mechanism of regulation of the interleukin-1 responsiveness” J. Immunol. 161: 6871-6877. PMID: 9862719
    DESCRIPTION OF THE NOVEL IL-1 INHIBITORY MECHANISM CALLED “CO-RECEPTOR COMPETITION”
     
  • Casadio R, Frigimelica E, Bossù P, Neumann D, Martin MU, Tagliabue A, Boraschi D (2001) “Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1β/IL-1RI complex” FEBS Lett. 499: 65-68. PMID: 11418113
    THE FIRST MODEL OF IL-1/IL-1R1/IL-1R3 INTERACTION, LARGELY CONFIRMED BY PARTIAL STRUCTURAL DATA OVER 10 YEARS LATER
     
  •  Bossù P, Neumann D, Del Giudice E, Ciaramella A, Gloaguen I, Fantuzzi G, Dinarello CA, Di Carlo E, MusianiP,  Meroni PL, Caselli G, Ruggiero P, Boraschi D (2003) “IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease” Proc. Natl. Acad. Sci. USA 100: 14181-14186. PMID: 14615579
    THE FIRST DESCRIPTION OF A PATHOLOGICAL ROLE FOR IL-18 IN AUTOIMMUNITY
  • Dinarello CA, Arend W, Sims J, Smith D, Blumberg H, O’Neill L, Goldbach-Mansky R, Pizarro T, Hoffman H, Bufler P, Nold M, Ghezzi P, Mantovani A, Garlanda C, Boraschi D, Rubartelli A, Netea M, van der Meer J, Joosten L, Mandrup-Poulsen T, Donath M, Lewis E, Pfeilschifter J, Martin M, Kracht M, Muehl H, Novick D, Lukic M, Conti B, Solinger A, van de Veerdonk F, Gabel C (2010) “IL-1 family nomenclature” Nat. Immunol. 11: 973. doi: 10.1038/ni1110-973. PMID: 20959797
    THE NEW NOMENCLATURE FOR THE CYTOKINES OF THE IL-1 FAMILY
     
  • Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, Mangelberger D, Oostingh GJ, Pfaller T, Pixner C, Posselt G, Italiani P, Nold MF, Nold-Petry CA, Bufler P, Dinarello CA (2011) “IL-37: a new anti-inflammatory cytokine of the IL-1 family” Eur. Cytokine Netw. 22: 127-147. doi: 10.1684/ecn.2011.0288. PMID: 22047735
    THE MOST EXTENSIVE AND CRITICAL OVERVIEW OF THE NEWEST CYTOKINE OF THE IL-1 FAMILY 
  • Boraschi D, Costantino L, Italiani P (2012) “Interaction of nanoparticles with immunocompetent cells: nanosafety considerations”Nanomedicine (Future Medicine) 7: 121-131. doi: 10.2217/nnm.11.169. PMID: 22191781
    THE MOST CITED INTRODUCTION TO THE IMMUNOSAFETY OF NANOMATERIALS
     
  • Boraschi D, Aguado MT, Dutel C, Goronzy J, Louis J, Grubeck-Loebenstein B, Rappuoli R, Del Giudice G (2013) “The gracefully aging immune system” Sci. Transl. Med. 5:185ps8. doi: 10.1126/scitranslmed.3005624. PMID: 23677590
    A CRITICAL EVALUATION OF THE STATE-OF-THE-ART AND NEW IMMUNE-RELATED SOLUTIONS TO THE PROBLEM OF HEALTHY AGEING 
     
  • Boraschi D, Tagliabue A (2013) ”The Interleukin-1 receptor family” Sem. Immunol. 25: 394-407. doi: 10.1016/j.smim.2013.10.023. PMID: 24246227
    THE MOST COMPLETE CRITICAL UPDATE ON THE RECEPTORS OF THE IL-1 FAMILY AND THEIR FUNCTIONAL ROLE IN DIFFERENT TISSUES
     
  • Boraschi D, Duschl A (authors/editors) (2014) “Nanoparticles and the immune system: safety and effects” Elsevier – Academic Press, Oxford, UK. ISBN: 978-0-12-408085-0
    THE FIRST FULL BOOK ADDRESSING THE NEW ISSUE OF IMMUNO-NANO-TOXICOLOGY
     
  • Italiani P, Mazza EM, Lucchesi D, Cifola I, Gemelli C, Grande A, Battaglia C, Bicciato S, Boraschi D (2014) “Transcriptomic profiling of the development of the inflammatory response in human monocytes in vitro PloSONE 3;9(2):e87680. doi: 10.1371/journal.pone.0087680. PMID:24498352
    A FUNDAMENTAL STUDY DESCRIBING THE KINETICS OF MONOCYTE TO MACROPHAGE TRANSITION AND MODULATION OF ACTIVATION DURING AN INFLAMMATORY REACTION
     
  • Italiani P, Boraschi D (2014) ”From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation” Front. Immunol. 5:514. doi: 10.3389/fimmu.2014.00514. PMID: 25368618
    THE MOST COMPLETE OVERVIEW OF THE ORIGIN AND DEVELOPMENT OF MACROPHAGES AND OF THEIR FUNCTIONAL PROGRAMMING

Group

 

Name                                     Position                            e.mail
Paola Italiani    researcher    p.italiani@ibp.cnr.it
Daniela Melillo

PostDoc    

d.melillo@ibp.cnr.it
Mariusz Madej PhD Studentm.madej@ibp.cnr.it

Gergö Sipos

PhD Studentg.sipos@ibp.cnr.it
Giacomo Della Cameraundergraduate student     g.dellacamera@ibp.cnr.it